Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Walt Disney Co (DIS) vs TransMedics Group Inc (TMDX) Price & Performance

Walt Disney CoTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Walt Disney Co vs TransMedics Group Inc — how do they compare? Walt Disney Co trades at $103.08 (market cap $178.76B), while TransMedics Group Inc trades at $87.35 (market cap $3.10B). The key difference: Walt Disney Co is far larger — about 57.7× TransMedics Group Inc's market cap, and Walt Disney Co pays a 1.45% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

DISTMDX
Market Cap
$178.76B$3.10B
Volume
7,546,013
Sector
MediaTechnology
52-Week High
$118.86$150.42
52-Week Low
$92.40$61.99
Enterprise Value
$219.62B$3.49B
Dividend Yield
1.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Walt Disney Co

Disney (DIS) trades at $103.20, down 1.62% on the day, amid a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $2.06 exceeding estimates by $0.20. Revenue growth has been steady, reaching $94.43 billion in 2025, while net income surged to $12.40 billion. Analyst sentiment remains positive with a consensus price target of $126.00, representing a 22% upside. Recent news highlights advertising opportunities with major events like the Super Bowl and ongoing FCC regulatory challenges.

The outlook for Disney is favorable, driven by earnings momentum, strategic investments in parks and streaming, and a dominant position in entertainment. Key risks include regulatory disputes with the FCC, box office underperformance of recent films, and economic sensitivity. With a P/E of 21.35 and robust cash flow, the stock offers value for long-term investors despite near-term volatility.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.

The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.

Returns comparison

Trailing returns across standard periods

About Walt Disney Co

The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.

Read more on DIS

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX